June 25, 2024

Antidiabetics Market Size to Rake USD 227.50 Billion by 2033

The global antidiabetics market size accounted for US$ 98.20 billion in 2023 and is projected to reach around USD 227.50 billion by 2033, growing at a CAGR of 8.76% from 2024 to 2033.

Key Points

  • North America has held the largest revenue share of around 39% in 2023.
  • Asia Pacific is observed to witness the fastest rate of expansion during the forecast period.
  • By product, the insulin segment dominated the antidiabetics market with the highest share in 2023.
  • By product, the drug class segment is observed to grow at a significant rate during the forecast period.
  • By patient population, the geriatric segment held the dominating share of the market in 2023.
  • By route of administration, the oral segment led the market in 2023. The segment is observed to sustain the position.
  • By route of administration, the insulin pen/syringe segment is observed to witness the fastest rate of expansion throughout the forecast period.

Antidiabetics Market Size 2024 to 2033

Report Summary

The global antidiabetics market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.

The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the antidiabetics market across the globe.

A comprehensive estimate on the antidiabetics market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of antidiabetics during the forecast period. Price point comparison by region with global average price is also considered in the study.

Download Access to a Free Copy of Our Latest Sample Report@  https://www.precedenceresearch.com/sample/3914 

Antidiabetics Market Scope

Report Coverage Details
Growth Rate from 2024 to 2033 CAGR of 8.76%
Global Market Size in 2023 USD 98.20 Billion
Global Market Size by 2033 USD 227.50 Billion
U.S. Market Size in 2023 USD 30.26 Billion
U.S. Market Size by 2033 USD 70.09 Billion
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered By Product, By Patient Population, and By Route of Administration
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Key Highlights:

Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized antidiabetics market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.

Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.

Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.

Also Read:  AI in Computer Vision Market Size to Attain USD 274.80 Bn by 2033

Market Players

The report includes the profiles of key antidiabetics market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.

Recent Development

  • In February 2023, IOL Chemicals and Pharmaceuticals Ltd, a leading pharmaceutical company’s share increased 12.1% and noticed the 8.25% higher at Rs 437.3 piece during the intraday session. The price of stock increased after the announcement of the antidiabetic drug ‘Metformin Hydrochloride’ approved by China’s drug supervisor.
  • In February 2024, Boehringer Ingelheim launched an antidiabetic drug in India for the treatment of chronic kidney dieases getting approval from the Central Drugs Standard Control Organization (CDSCO).
  • In January 2024, Glenmark Pharmaceuticals launched the antidiabetic drug a biosimilar of the Liraglutide a famous antidiabetic drug. The drug gets approval from the Drug Controller General of India (DCGI).
  • In January 2022, the Danish Drug Maker, Novo Nordisk introduce the launch of anti-diabetics drug semaglutide in India for the Type 2 diabetes treatment.

Antidiabetic Market Companies

  • Sanofi-Aventis
  • Takeda Pharmaceuticals
  • Eli Lilly
  • Oramed Pharmaceuticals
  • Boehringer Ingelheim
  • Merck & Co. Inc.
  • Novo Nordisk
  • Bristol-Myers Squibb
  • Halozyme Therapeutics
  • Pfizer

Segments Covered in the Report

By Product

  • Insulin
    • Rapid Acting
    • Long Acting
    • Premixed Insulin
    • Short Acting
  • Drug Class
    • Biguanides
    • GLP-Agonists
    • Thiazolidinediones
    • Sulphonylureas
    • SGLT-2
    • Alpha-Glucosidase Inhibitors
    • DPP-4 Inhibitors
    • Meglitinides

By Patient Population

  • Pediatric
  • Adults
  • Geriatric

By Route of Administration

  • Oral
  • Infusion
  • Intravenous
  • Insulin Pump
  • Insulin Pen/Syringe

Regional Segmentation

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
  • Latin America (Brazil and Rest of Latin America)
  • Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Research Methodology

Secondary Research

It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.

The secondary research sources referred in the process are as follows:

  • Governmental bodies, and organizations creating economic policies
  • National and international social welfare institutions
  • Company websites, financial reports and SEC filings, broker and investor reports
  • Related patent and regulatory databases
  • Statistical databases and market reports
  • Corporate Presentations, news, press release, and specification sheet of Manufacturers

Primary Research

Primary research includes face-to-face interviews, online surveys, and telephonic interviews.

  • Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
  • In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Antidiabetics Market 

5.1. COVID-19 Landscape: Antidiabetics Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Antidiabetics Market, By Product

8.1. Antidiabetics Market Revenue and Volume, by Product, 2024-2033

8.1.1 Insulin

8.1.1.1. Market Revenue and Volume Forecast (2021-2033)

8.1.2. Drug Class

8.1.2.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 9. Global Antidiabetics Market, By Patient Population

9.1. Antidiabetics Market Revenue and Volume, by Patient Population, 2024-2033

9.1.1. Pediatric

9.1.1.1. Market Revenue and Volume Forecast (2021-2033)

9.1.2. Adults

9.1.2.1. Market Revenue and Volume Forecast (2021-2033)

9.1.3. Geriatric

9.1.3.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 10. Global Antidiabetics Market, By Route of Administration 

10.1. Antidiabetics Market Revenue and Volume, by Route of Administration, 2024-2033

10.1.1. Oral

10.1.1.1. Market Revenue and Volume Forecast (2021-2033)

10.1.2. Infusion

10.1.2.1. Market Revenue and Volume Forecast (2021-2033)

10.1.3. Intravenous

10.1.3.1. Market Revenue and Volume Forecast (2021-2033)

10.1.4. Insulin Pump

10.1.4.1. Market Revenue and Volume Forecast (2021-2033)

10.1.5. Insulin Pen/Syringe

10.1.5.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 11. Global Antidiabetics Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.1.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)

11.1.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.1.4.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)

11.1.4.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.1.5.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)

11.1.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.2.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)

11.2.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.2.4.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)

11.2.4.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.2.5.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)

11.2.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.2.6.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)

11.2.6.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.2.7.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)

11.2.7.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.3.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)

11.3.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.3.4.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)

11.3.4.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.3.5.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)

11.3.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.3.6.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)

11.3.6.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.3.7.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)

11.3.7.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.4.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)

11.4.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.4.4.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)

11.4.4.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.4.5.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)

11.4.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.4.6.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)

11.4.6.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.4.7.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)

11.4.7.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.5.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)

11.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.5.4.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)

11.5.4.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.5.5.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)

11.5.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

Chapter 12. Company Profiles

12.1. Sanofi-Aventis

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Takeda Pharmaceuticals

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Eli Lilly

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Oramed Pharmaceuticals

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Boehringer Ingelheim

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Merck & Co. Inc.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Novo Nordisk

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Bristol-Myers Squibb

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Halozyme Therapeutics

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Pfizer

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Emailsales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com


Prathamesh

Leave a Reply

Your email address will not be published. Required fields are marked *